8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 19, 2026·SEC
Theravance Biopharma, Inc.(TBPH)Earnings, Financials & Key Ratios
TBPH•NASDAQ
8.0× P/E·Price updated Jun 19, 2026
AboutTheravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.Show more
- Revenue$107M+66.9%
- EBITDA-$8M+82.2%
- Net Income$106M+287.7%
- EPS (Diluted)2.06+279.1%
- Gross Margin94.87%-5.1%
- EBITDA Margin-7.19%+89.3%
- Operating Margin-12.33%+83.1%
- Net Margin98.54%+212.4%
- ROE44.85%+254.4%
TBPH Key Insights
Theravance Biopharma, Inc. (TBPH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 221.9% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy 5Y average net margin of 250.6%
✗Weaknesses
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TBPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TBPH Price & Volume
Theravance Biopharma, Inc. (TBPH) stock price & volume — 10-year historical chart
Loading chart...
TBPH Growth Metrics
Theravance Biopharma, Inc. (TBPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years9.82%
5 Years8.38%
3 Years27.91%
TTM68.2%
Profit CAGR
10 Years-
5 Years-
3 Years-50.48%
TTM296.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM286.76%
Return on Capital
10 Years-44.02%
5 Years-25.54%
3 Years-9.75%
Last Year-3.44%
TBPH Recent Earnings
Theravance Biopharma, Inc. (TBPH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.10-443.6%
$0.03
Rev
$18M-0.5%
$18M
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.06-86.4%
$0.44
Rev
$46M-18.9%
$57M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.04+233.3%
$0.03
Rev
$20M-53.6%
$43M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.08+42.9%
$0.14
Rev
$26M+39.9%
$19M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.10vs $0.03-443.6% | $18Mvs $18M-0.5% |
| Q2 2026 | Mar 19, 2026 | $0.06vs $0.44-86.4% | $46Mvs $57M-18.9% |
| Q4 2025 | Nov 10, 2025 | $0.04vs $0.03+233.3% | $20Mvs $43M-53.6% |
| Q3 2025 | Aug 12, 2025 | $0.08vs $0.14+42.9% | $26Mvs $19M+39.9% |
Based on last 12 quarters of dataView full earnings history →
TBPH Peer Comparison
Theravance Biopharma, Inc. (TBPH) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PCRX | 878.35M | 22.33 | 139.56 | 3.63% | 1.27% | 1.31% | 0.66 | |
 INSM | 20.76B | 95.80 | -14.95 | 66.73% | -144.44% | -130.11% | 1.04 | |
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 |
Compare TBPH vs Peers
Theravance Biopharma, Inc. (TBPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TBPH Income Statement
Theravance Biopharma, Inc. (TBPH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 15.39M | 60.37M | 73.41M | 71.86M | 55.31M | 51.35M | 57.42M | 64.38M | 107.46M | 109.78M |
Revenue Growth % | -68.37% | 292.37% | 21.61% | -2.12% | -23.03% | -7.17% | 11.84% | 12.12% | 66.92% | 68.2% |
Cost of Goods Sold | 6.03M | 715K | 0 | 0 | 193.66M | 63.39M | 40.62M | 0 | 5.51M | 21.55M |
COGS % of Revenue | 39.19% | 1.18% | - | - | 350.12% | 123.46% | 70.74% | - | 5.13% | - |
Gross Profit | 9.36M▲ 0% | 59.66M▲ 537.6% | 73.41M▲ 23.1% | 71.86M▼ 2.1% | -138.35M▼ 292.5% | -12.05M▲ 91.3% | 16.8M▲ 239.5% | 64.38M▲ 283.2% | 101.95M▲ 58.4% | 88.23M▲ 0% |
Gross Margin % | 60.81% | 98.82% | 100% | 100% | -250.12% | -23.46% | 29.26% | 100% | 94.87% | 80.37% |
Gross Profit Growth % | -79.55% | 537.61% | 23.06% | -2.12% | -292.53% | 91.29% | 239.49% | 283.15% | 58.35% | - |
Operating Expenses | 269.48M | 298.41M | 325.33M | 369.48M | 119.44M | 79.91M | 72.84M | 111.33M | 115.19M | 88.14M |
OpEx % of Revenue | 1751.46% | 494.3% | 443.14% | 514.19% | 215.94% | 155.63% | 126.84% | 172.92% | 107.19% | - |
Selling, General & Admin | 95.59M | 97.06M | 106.08M | 108.53M | 99.3M | 67.07M | 70.45M | 69.17M | 73.65M | 37.58M |
SG&A % of Revenue | 621.29% | 160.77% | 144.5% | 151.04% | 179.52% | 130.63% | 122.69% | 107.44% | 68.54% | - |
Research & Development | 173.89M | 201.35M | 219.25M | 260.95M | 201.55M | 70.07M | 46.34M | 37.64M | 37.41M | 31.39M |
R&D % of Revenue | 1130.16% | 333.52% | 298.65% | 363.16% | 364.39% | 136.47% | 80.7% | 58.47% | 34.82% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | -181.41M | -57.24M | -43.96M | 4.51M | 4.13M | 3M |
Operating Income | -260.12M▲ 0% | -238.75M▲ 8.2% | -251.91M▼ 5.5% | -297.63M▼ 18.1% | -257.78M▲ 13.4% | -91.96M▲ 64.3% | -56.03M▲ 39.1% | -46.95M▲ 16.2% | -13.25M▲ 71.8% | 88K▲ 0% |
Operating Margin % | -1690.65% | -395.48% | -343.14% | -414.19% | -466.06% | -179.09% | -97.58% | -72.92% | -12.33% | 0.08% |
Operating Income Growth % | -44.14% | 8.22% | -5.51% | -18.15% | 13.39% | 64.33% | 39.06% | 16.21% | 71.79% | - |
EBITDA | -256.1M | -235.59M | -245.7M | -290.65M | -252.97M | -88.92M | -54.03M | -43.33M | -7.73M | 3.85M |
EBITDA Margin % | -1664.47% | -390.24% | -334.68% | -404.49% | -457.36% | -173.18% | -94.1% | -67.31% | -7.19% | 3.51% |
EBITDA Growth % | -44.4% | 8.01% | -4.29% | -18.3% | 12.96% | 64.85% | 39.23% | 19.8% | 82.16% | 107.98% |
D&A (Non-Cash Add-back) | 4.03M | 3.17M | 6.21M | 6.97M | 4.81M | 3.04M | 2M | 3.62M | 5.51M | 3.76M |
EBIT | -263.16M | -215.6M | -209.81M | -294.8M | -237.64M | -79.12M | -53.65M | -42.07M | -13.25M | 4.23M |
Net Interest Income | -3.76M | 1.48M | -23.47M | -4.11M | -7.44M | 2.18M | 6.77M | 2.33M | -2.46M | -362K |
Interest Income | 4.79M | 11.97M | 8.39M | 4.44M | 1.11M | 8.54M | 9.12M | 4.88M | 0 | 1.46M |
Interest Expense | 8.55M | 10.48M | 31.86M | 8.55M | 8.55M | 6.37M | 2.35M | 2.55M | 2.46M | 1.82M |
Other Income/Expense | -11.59M | 12.67M | 10.24M | -5.72M | -7.44M | -858K | 6.77M | 2.33M | 142.49M | 136.83M |
Pretax Income | -271.71M▲ 0% | -226.09M▲ 16.8% | -241.68M▼ 6.9% | -303.34M▼ 25.5% | -265.22M▲ 12.6% | -92.81M▲ 65.0% | -49.27M▲ 46.9% | -44.61M▲ 9.4% | 129.25M▲ 389.7% | 136.92M▲ 0% |
Pretax Margin % | -1765.96% | -374.5% | -329.2% | -422.15% | -479.51% | -180.76% | -85.8% | -69.3% | 120.27% | 124.72% |
Income Tax | 13.69M | -10.56M | -5.22M | -8.52M | -151K | 9K | 5.92M | 11.8M | 23.35M | 22.37M |
Effective Tax Rate % | -5.04% | 4.67% | 2.16% | 2.81% | 0.06% | -0.01% | -12.02% | -26.46% | 18.07% | 16.34% |
Net Income | -285.4M▲ 0% | -215.52M▲ 24.5% | -236.46M▼ 9.7% | -278.02M▼ 17.6% | -199.43M▲ 28.3% | 872.13M▲ 537.3% | -55.19M▼ 106.3% | -56.42M▼ 2.2% | 105.89M▲ 287.7% | 114.54M▲ 0% |
Net Margin % | -1854.97% | -357.01% | -322.08% | -386.9% | -360.55% | 1698.54% | -96.11% | -87.63% | 98.54% | 104.34% |
Net Income Growth % | -49.69% | 24.48% | -9.71% | -17.58% | 28.27% | 537.32% | -106.33% | -2.22% | 287.7% | 296.36% |
Net Income (Continuing) | -285.4M | -215.52M | -236.46M | -294.82M | -265.07M | -92.82M | -55.19M | -56.42M | 105.89M | 114.54M |
Discontinued Operations | 0 | 0 | 0 | 16.81M | 65.64M | 964.96M | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -5.45▲ 0% | -3.99▲ 26.8% | -4.25▼ 6.5% | -4.46▼ 4.9% | -2.87▲ 35.7% | -1.26▲ 56.1% | -1.00▲ 20.6% | -1.15▼ 15.0% | 2.06▲ 279.1% | 2.23▲ 0% |
EPS Growth % | -27.93% | 26.79% | -6.52% | -4.94% | 35.65% | 56.1% | 20.63% | -15% | 279.13% | 286.76% |
EPS (Basic) | -5.45 | -3.99 | -4.25 | -4.46 | -2.87 | -1.26 | -1.00 | -1.15 | 2.10 | - |
Diluted Shares Outstanding | 52.35M | 53.97M | 55.61M | 62.34M | 69.46M | 73.59M | 55.3M | 48.85M | 51.51M | 51.28M |
Basic Shares Outstanding | 52.35M | 53.97M | 55.61M | 62.34M | 69.46M | 73.59M | 55.3M | 48.85M | 50.32M | 51.28M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TBPH Balance Sheet
Theravance Biopharma, Inc. (TBPH) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 378.75M | 532.82M | 338.49M | 393.34M | 249.87M | 353.46M | 133.54M | 161.07M | 418.46M | 417.63M |
Cash & Short-Term Investments | 348.57M | 505.28M | 280.83M | 292.94M | 173.47M | 327.48M | 102.43M | 88.35M | 315.36M | 394.67M |
Cash Only | 88.98M | 378.02M | 58.06M | 81.47M | 89.96M | 298.17M | 39.55M | 37.8M | 167.81M | 288.1M |
Short-Term Investments | 259.59M | 127.25M | 222.77M | 211.47M | 83.51M | 29.31M | 62.88M | 50.55M | 147.55M | 106.56M |
Accounts Receivable | 9.36M | 10.67M | 50.57M | 69.67M | 57.6M | 16.79M | 17.47M | 68.44M | 95.54M | 15.58M |
Days Sales Outstanding | 222.09 | 64.53 | 251.42 | 353.88 | 380.1 | 119.32 | 111.07 | 388.01 | 324.5 | 125.77 |
Inventory | 16.83M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 1.02K | - | - | - | - | - | - | - | - | - |
Other Current Assets | 3.7M | 0 | 7.09M | 10.36M | 8.56M | 7.68M | 11.6M | 4.2M | 7.56M | 7.38M |
Total Non-Current Assets | 62.65M | 27.41M | 70.34M | 75.72M | 124.95M | 253.94M | 248.46M | 193.09M | 67.11M | 54.68M |
Property, Plant & Equipment | 10.16M | 13.18M | 59.25M | 59.68M | 53.35M | 52M | 45.35M | 35.77M | 30.27M | 28.54M |
Fixed Asset Turnover | 1.51x | 4.58x | 1.24x | 1.20x | 1.04x | 0.99x | 1.27x | 1.80x | 3.55x | 3.55x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 41.59M | 11.87M | 9.5M | 833K | 68.37M | 0 | 0 | 0 | 14.35M | 18.21M |
Other Non-Current Assets | 10.91M | 2.37M | 1.59M | 15.2M | 3.23M | 201.94M | 203.1M | 157.32M | 22.5M | 25.3M |
Total Assets | 441.4M▲ 0% | 560.24M▲ 26.9% | 408.83M▼ 27.0% | 469.06M▲ 14.7% | 374.82M▼ 20.1% | 607.4M▲ 62.1% | 382M▼ 37.1% | 354.16M▼ 7.3% | 485.57M▲ 37.1% | 472.31M▲ 0% |
Asset Turnover | 0.03x | 0.11x | 0.18x | 0.15x | 0.15x | 0.08x | 0.15x | 0.18x | 0.22x | 0.24x |
Asset Growth % | -30.95% | 26.92% | -27.03% | 14.73% | -20.09% | 62.05% | -37.11% | -7.29% | 37.1% | 108.92% |
Total Current Liabilities | 62.55M | 98.55M | 111.7M | 123.57M | 58.59M | 28.71M | 24.77M | 32.09M | 38.3M | 31.77M |
Accounts Payable | 5.92M | 9.03M | 4.76M | 6.78M | 3.1M | 1.55M | 1.52M | 2.24M | 2.57M | 1.1M |
Days Payables Outstanding | 358.58 | 4.61K | - | - | 5.84 | 8.95 | 13.69 | - | 169.96 | 32 |
Short-Term Debt | 0 | 0 | 17.61M | 29.2M | 17.44M | 0 | 0 | 0 | 10.95M | 10.75M |
Deferred Revenue (Current) | 125K | 43.4M | 31.57M | 11.52M | 98K | 24K | 0 | 0 | 0 | 0 |
Other Current Liabilities | 32.37M | 22.32M | 29.58M | 40.83M | 25.15M | -24K | 12.88M | 0 | 19.5M | 14.64M |
Current Ratio | 6.05x | 5.41x | 3.03x | 3.18x | 4.26x | 12.31x | 5.39x | 5.02x | 10.93x | 13.14x |
Quick Ratio | 5.79x | 5.41x | 3.03x | 3.18x | 4.26x | 12.31x | 5.39x | 5.02x | 10.93x | 13.14x |
Cash Conversion Cycle | 882.24 | - | - | - | - | - | - | - | - | 93.77 |
Total Non-Current Liabilities | 263.67M | 513.27M | 520.96M | 649.24M | 654.8M | 136.88M | 144.24M | 146.53M | 150.54M | 149.94M |
Long-Term Debt | 223.75M | 454.35M | 445.19M | 599.84M | 599.39M | 0 | 0 | 0 | 32.8M | 32.8M |
Capital Lease Obligations | 0 | 0 | 47.73M | 47.22M | 52.68M | 45.41M | 45.24M | 39.11M | 31.76M | 130.75M |
Deferred Tax Liabilities | 0 | -26.18M | 0 | 0 | 240K | 0 | 0 | 0 | 85.68M | 172.83M |
Other Non-Current Liabilities | 39.92M | 32.74M | 21.29M | 1.83M | 2.18M | 91.29M | 99M | 107.42M | 313K | 244K |
Total Liabilities | 326.22M | 611.82M | 632.67M | 772.81M | 713.39M | 165.6M | 169M | 178.62M | 188.85M | 181.72M |
Total Debt | 223.75M | 454.35M | 510.53M | 676.26M | 669.52M | 52.16M | 49.16M | 49.82M | 75.5M | 73.3M |
Net Debt | 134.77M | 76.33M | 452.46M | 594.79M | 579.56M | -246.01M | 9.61M | 12.02M | -92.31M | -214.8M |
Debt / Equity | 1.94x | - | - | - | - | 0.12x | 0.23x | 0.28x | 0.25x | 0.25x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | 19.04x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -55.81x |
Interest Coverage | -30.79x | -20.57x | -6.59x | -34.49x | -27.80x | -12.42x | -22.83x | -16.52x | -5.38x | 2.32x |
Total Equity | 115.18M▲ 0% | -51.59M▼ 144.8% | -223.84M▼ 333.9% | -303.75M▼ 35.7% | -338.57M▼ 11.5% | 441.8M▲ 230.5% | 213M▼ 51.8% | 175.54M▼ 17.6% | 296.72M▲ 69.0% | 290.59M▲ 0% |
Equity Growth % | -67.11% | -144.79% | -333.89% | -35.7% | -11.46% | 230.49% | -51.79% | -17.58% | 69.03% | 185.52% |
Book Value per Share | 2.20 | -0.96 | -4.03 | -4.87 | -4.87 | 6.00 | 3.85 | 3.59 | 5.76 | 5.67 |
Total Shareholders' Equity | 115.18M | -51.59M | -223.84M | -303.75M | -338.57M | 441.8M | 213M | 175.54M | 296.72M | 290.59M |
Common Stock | 1K | 1K | 1K | 1K | 1K | 1K | 0 | 0 | 1K | 1K |
Retained Earnings | -797.74M | -1.01B | -1.25B | -1.53B | -1.73B | -853.91M | -909.1M | -965.52M | -859.63M | -864.56M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -733K | -166K | 145K | 47K | 0 | -15K | -65K | 7K | 61K | -62K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TBPH Cash Flow Statement
Theravance Biopharma, Inc. (TBPH) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -201.05M | -112.87M | -238.2M | -250.4M | -207.86M | -186.99M | -27M | -11.54M | 238.54M | 268.78M |
Operating CF Margin % | -1306.72% | -186.96% | -324.46% | -348.47% | -375.8% | -364.18% | -47.01% | -17.92% | 221.97% | - |
Operating CF Growth % | -103.11% | 43.86% | -111.04% | -5.12% | 16.99% | 10.04% | 85.56% | 57.27% | 2167.98% | 4285.62% |
Net Income | -285.4M | -215.52M | -236.46M | -294.82M | -265.07M | -92.82M | -55.19M | -56.42M | 105.89M | 114.54M |
Depreciation & Amortization | 4.03M | 3.17M | 6.21M | 6.97M | 8.6M | 7.02M | 4.26M | 3.62M | 5.64M | 3.43M |
Stock-Based Compensation | 49.15M | 51.31M | 60.45M | 62.98M | 62.06M | 39.73M | 25.37M | 21.39M | 18.48M | 13.6M |
Deferred Taxes | 8.74M | -11.21M | 0 | 0 | 0 | 0 | 3.21M | -7.57M | -11.52M | -12.67M |
Other Non-Cash Items | 10K | -43K | -23.01M | 12.25M | 26.1M | -183.28M | 3.7M | 7.09M | -423K | -328.54M |
Working Capital Changes | 22.43M | 59.43M | -45.4M | -37.78M | -39.55M | 42.35M | -8.34M | 20.36M | 120.47M | 478.42M |
Change in Receivables | -1.61M | 1.63M | -15.02M | 6.13M | 1.8M | -2.72M | 0 | -966K | -27.1M | 176.65M |
Change in Inventory | -7.3M | -1.63M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 3.8M | 3.58M | -4.27M | 3.66M | -3.53M | -1.61M | 6K | 750K | 326K | -1.31M |
Cash from Investing | -56.33M | 176.71M | -83.05M | 10.72M | 124.49M | 1.15B | -32.7M | 12.28M | -105.28M | -83.32M |
Capital Expenditures | -2.41M | -7.24M | -3.18M | -6.62M | -3.41M | -572K | -2.49M | -332K | -42K | -42K |
CapEx % of Revenue | 15.64% | 11.99% | 4.33% | 9.21% | 6.16% | 1.11% | 4.33% | 0.52% | 0.04% | 0.04% |
Acquisitions | 0 | 20M | 5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -53.93M | 17K | 5K | 64K | 6K | 1.1B | 1.51M | 0 | 0 | 0 |
Cash from Financing | 1.66M | 225.2M | 1.29M | 263.08M | 91.86M | -758.81M | -198.93M | -2.5M | -3.25M | -7.97M |
Debt Issued (Net) | 0 | 229.44M | -2.15M | 144.65M | -10.73M | -631.6M | 0 | 0 | 0 | 0 |
Equity Issued (Net) | -8.56M | -9.81M | -3.17M | 130.17M | 99.12M | -132.28M | -199.55M | -3M | -3.25M | -7.97M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -8.56M | -9.81M | -3.17M | -9.75M | -9.06M | -132.28M | -199.55M | -3.1M | -4.03M | -8.98M |
Other Financing | 10.22M | 5.57M | 6.62M | -11.73M | 3.47M | 5.08M | 618K | 508K | 0 | 0 |
Net Change in Cash | -255.73M▲ 0% | 289.04M▲ 213.0% | -319.96M▼ 210.7% | 23.4M▲ 107.3% | 8.5M▼ 63.7% | 208.21M▲ 2350.7% | -258.63M▼ 224.2% | -1.75M▲ 99.3% | 130.01M▲ 7537.6% | 177.49M▲ 0% |
Free Cash Flow | -203.46M▲ 0% | -120.11M▲ 41.0% | -241.37M▼ 101.0% | -257.02M▼ 6.5% | -211.26M▲ 17.8% | -187.56M▲ 11.2% | -29.48M▲ 84.3% | -11.87M▲ 59.8% | 238.5M▲ 2109.8% | 268.74M▲ 0% |
FCF Margin % | -1322.36% | -198.95% | -328.78% | -357.68% | -381.96% | -365.29% | -51.35% | -18.43% | 221.93% | 244.81% |
FCF Growth % | -101.2% | 40.97% | -100.96% | -6.48% | 17.8% | 11.22% | 84.28% | 59.75% | 2109.77% | 732.4% |
FCF per Share | -3.89 | -2.23 | -4.34 | -4.12 | -3.04 | -2.55 | -0.53 | -0.24 | 4.63 | 5.24 |
FCF Conversion (FCF/Net Income) | 0.70x | 0.52x | 1.01x | 0.90x | 1.04x | -0.21x | 0.49x | 0.20x | 2.25x | 2.35x |
Interest Paid | 7.45M | 7.47M | 26.18M | 24.02M | 39.03M | 22.24M | 0 | 0 | 0 | 0 |
Taxes Paid | 4.93M | -7.32M | 22K | 14K | 0 | 117.97M | 24K | 109K | 0 | 8.9M |
TBPH Key Ratios
Theravance Biopharma, Inc. (TBPH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -122.65% | -677.87% | - | - | - | 1689.74% | -16.86% | -29.04% | 44.85% | 43.85% |
Return on Invested Capital (ROIC) | -81.6% | -130.38% | -149.14% | -85.91% | -72.68% | -31.58% | -20.09% | -17.17% | -5.07% | 0.07% |
Gross Margin | 60.81% | 98.82% | 100% | 100% | -250.12% | -23.46% | 29.26% | 100% | 94.87% | 80.37% |
Net Margin | -1854.97% | -357.01% | -322.08% | -386.9% | -360.55% | 1698.54% | -96.11% | -87.63% | 98.54% | 104.34% |
Debt / Equity | 1.94x | - | - | - | - | 0.12x | 0.23x | 0.28x | 0.25x | 0.25x |
Interest Coverage | -30.79x | -20.57x | -6.59x | -34.49x | -27.80x | -12.42x | -22.83x | -16.52x | -5.38x | 2.32x |
FCF Conversion | 0.70x | 0.52x | 1.01x | 0.90x | 1.04x | -0.21x | 0.49x | 0.20x | 2.25x | 2.35x |
Revenue Growth | -68.37% | 292.37% | 21.61% | -2.12% | -23.03% | -7.17% | 11.84% | 12.12% | 66.92% | 68.2% |
Related:TBPH Dividend History·TBPH Revenue History·TBPH Price History·TBPH P/E History·TBPH Financial Ratios·TBPH Institutional Holders
TBPH SEC Filings & Documents
Theravance Biopharma, Inc. (TBPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
TBPH Frequently Asked Questions
Theravance Biopharma, Inc. (TBPH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Theravance Biopharma, Inc. (TBPH) reported $109.8M in revenue for fiscal year 2025. This represents a 639% increase from $14.9M in 2011.
Theravance Biopharma, Inc. (TBPH) grew revenue by 66.9% over the past year. This is strong growth.
Yes, Theravance Biopharma, Inc. (TBPH) is profitable, generating $114.5M in net income for fiscal year 2025 (98.5% net margin).
Dividend & Returns
Theravance Biopharma, Inc. (TBPH) has a return on equity (ROE) of 44.8%. This is excellent, indicating efficient use of shareholder capital.
Theravance Biopharma, Inc. (TBPH) generated $268.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.